ddp4 inhibitor and glp 1 agonist do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance SGLT-2 inhibitors, GLP-1 Receptor Agonists Have better

In subsequent Phase 2 trials, once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 8 mg, and 12 mg resulted in marked improvements in glycemic control compared to placebo, along with substantial weight loss when contrasted with placebo and dulaglutide (1.5 mg)

Recently published four-arm target trial which included 283 998 patients compared effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors and sulfonylureas

Current research has not established a minimum effective dose, though studies most commonly examine 5 to 10 grams of allulose

Some studies show there may be a slight effect on GLP-1 levels from green tea, probiotics, and berberine

NCBI Bookshelf

Mann JF, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, et al